Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 7/20 | 0.40 |
| ▸ | CTSS | P25774 | 2/20 | 0.40 |
| ▸ | HTR2C | P28335 | 5/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.38 |
| ▸ | CTSL | P07711 | 2/20 | 0.36 |
| ▸ | CTSB | P07858 | 2/20 | 0.36 |
| ▸ | CTSH | P09668 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.32 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.32 |
| ▸ | REN | P00797 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3639189 | 1.00 | CTSK (0.40) | CTSKCTSSHTR2CSLC6A4CTSL | |
| SCHEMBL3770470 | 0.82 | CTSK (0.37) | CTSKCTSSHTR2CSLC6A4CTSL | |
| SCHEMBL3770473 | 0.82 | CTSK (0.37) | CTSKCTSSHTR2CSLC6A4CTSL | |
| SCHEMBL2990720 | 0.81 | CTSK (0.41) | CTSKCTSSHTR2CSLC6A4CTSL | |
| SCHEMBL499190 | 0.80 | CTSK (0.40) | CTSKCTSSHTR2CSLC6A4CTSL | |
| SCHEMBL499191 | 0.80 | CTSK (0.40) | CTSKCTSSHTR2CSLC6A4CTSL | |
| SCHEMBL24991144 | 0.77 | CTSK (0.37) | CTSKCTSSHTR2CSLC6A4CTSL | |
| SCHEMBL8911411 | 0.74 | HTR2C (0.42) | CTSKCTSSHTR2CSLC6A4CTSL | |
| SCHEMBL21574018 | 0.74 | HTR2C (0.42) | CTSKCTSSHTR2CSLC6A4CTSL | |
| SCHEMBL4803683 | 0.74 | CTSK (0.39) | CTSKCTSSHTR2CSLC6A4CTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100317697-A1 | Renin Inhibitors | VITAE PHARMACEUTICALS, INC. | 2010-12-16 | — | — | US | disclosed |
| EP-2167609-A1 | RENIN INHIBITORS | Vitae Pharmaceuticals, Inc. (US) | 2010-03-31 | — | — | EP | disclosed |
| WO-2009096996-A1 | RENIN INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317697-A1 | Renin Inhibitors | REN, ACE, SERPINB1 | CTSK 95/4885CTSS 91/4885HTR2C 4565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.